MELANOMA MORTALITY IN THE STATE OF RIO DE JANEIRO: EPIDEMIOLOGICAL TIME SERIES ANALYSIS BETWEEN 2002 AND 2022
DOI:
https://doi.org/10.56238/arev7n8-118Keywords:
Melanoma, Mortality, Epidemiology, Skin NeoplasmsAbstract
Introduction: Cutaneous melanoma is the most lethal form of skin cancer and, when diagnosed late, has a high mortality rate. Up-to-date regional data are essential to inform health policies. Objectives: To analyze the clinical and epidemiological profile of melanoma deaths in the state of Rio de Janeiro between 2002 and 2022, based on data from the Mortality Information System (SIM). Methods: This was a retrospective cross-sectional study with secondary data extracted from DATASUS. Variables such as sex, age, race/color, education, place of death, and calculation of potential years of life lost (PYLL) were analyzed. The analyses were descriptive, grouped by five-year periods. Results: Most deaths occurred in white men with low education, concentrated between the ages of 60 and 79. PYLL was most significant between the ages of 40 and 59. A proportional increase in PYLL was observed in women and non-white individuals over the years. Conclusion: The study highlights the impact of melanoma on vulnerable populations and reinforces the need for preventive strategies and early screening targeted at higher-risk groups.
Downloads
References
AHMED, B.; QADIR, M. I.; GHAFOOR, S. Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Critical Reviews in Eukaryotic Gene Expression, v. 30, n. 4, p. 291-297, 2020. Acesso em: maio 2025. DOI: 10.1615/CritRevEukaryotGeneExpr.2020028454.
ALBERT, V. A.; KOH, H. K.; GELLER, A. C.; MILLER, D. R.; PROUT, M. N.; LEW, R. A. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. Journal of the American Academy of Dermatology, v. 23, n. 2, p. 308–310, 1990. Acesso em: jun. 2025. DOI: https://doi.org/10.1016/0190-9622(90)70214-3.
DZWIERZYNSKI, W. W. Melanoma risk factors and prevention. Clinics in Plastic Surgery, v. 48, n. 4, p. 543–550, out. 2021. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34503715/. Acesso em: maio 2025.
FINARDI, R. C.; CASAGRANDE, D.; OLIVEIRA, A. P.; MIRANDOLA, D.; GERALDINO, T. H.; CARVALHO, L. M. N.; MARTINS, C. L. C. S.; LADISLAU, L. A. Patient profile and characterization of advanced melanoma treatment in two private cancer centers in Brazil: a real-world study. JAFF, v. 10, n. 2, 2025. Disponível em: https://doi.org/10.22563/2525-7323.2025.v10.e00171. Acesso em: jun. 2025.
GUY, G. P.; EKWUEME, D. U. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer. Pharmacoeconomics, v. 29, n. 10, p. 863–874, 2011. DOI: 10.2165/11589300-000000000-00000. Acesso em: maio 2025.
IBGE EDUCA. Desigualdades sociais por cor ou raça no Brasil. 2019. Disponível em: https://educa.ibge.gov.br/jovens/materias-especiais/21039-desigualdades-sociais-por-cor-ouraca-no-brasil.html. Acesso em: 5 jun. 2025.
LODDE, G.; ZIMMER, L.; LIVINGSTONE, E.; SCHADENDORF, D.; UGUREL, S. Malignant melanoma. Hautarzt, v. 71, n. 1, p. 63–77, 2020. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31773173. Acesso em: maio 2025.
PEREIRA, T. G. G.; LEAL, T. A. M. C.; SANTANA, L. U.; TSUGAMI, M. C.; CHEN, V. P.; BARROS, Y. C.; ALMEIDA, P. R. M. N.; XAVIER, T. P. Epidemiology outic options. Melanoma and non-melanoma skin tumors: a comparison of incidence, mortality, and therape. Rev DELOS, v. 18, n. 63, p. e3620, 2025. Disponível em: https://doi.org/10.55905/rdelosv18.n63-099. Acesso em: jun. 2025.
RAIMONDI, S.; SUPPA, M.; GANDINI, S. Melanoma epidemiology and sun exposure. Acta Dermato-Venereologica, v. 100, n. 11, p. adv00136, 2020. DOI: 10.2340/00015555-3491. Acesso em: jun. 2025.
RENZI, M.; SCHIMMEL, J.; DECKER, A.; LAWRENCE, N. Management of skin cancer in the elderly. Dermatologic Clinics, v. 37, n. 3, p. 279–286, 2019. DOI: 10.1016/j.det.2019.02.003. Acesso em: jun. 2025.
SCHADENDORF, D.; VAN AKKOOI, A. C. J.; BERKING, C.; GRIEWANK, K. G.; GUTZMER, R.; HAUSCHILD, A.; et al. Melanoma. The Lancet, v. 392, n. 10151, p. 971–984, 2018. DOI: 10.1016/S0140-6736(18)31559-9. Acesso em: jun. 2025.
SILVA, G. R.; FERREIRA, L. B.; GIMBA, E. R. P. Expression and prognostic potential of osteopontin splice variants in malignant melanoma. Clinical and Translational Science, v. 17, n. 8, p. e70002, ago. 2024. DOI: 10.1111/cts.70002. PMID: 39152618; PMCID: PMC11329566. Acesso em: maio 2025.
STRASHILOV, S.; YORDANOV, A. Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances. International Journal of Molecular Sciences, v. 22, n. 12, p. 6395, jun. 2021. Disponível em: https://www.mdpi.com/1422-0067/22/12/6395. Acesso em: jun. 2025.
WANG, S. J.; XIU, J.; BUTCHER, K. M.; DECLERCK, B. K.; KIM, G. H.; MOSER, J.; GIBNEY, G. T.; HERNANDEZ-AYA, L. F.; LUTZKY, J.; ABDULLA, F.; MARGOLIN, K. A.; POSSIK, P. A.; ROBLES-ESPINOZA, C. D.; ITO, F.; IN, G. K. Comprehensive profiling of acral lentiginous melanoma reveals downregulated immune activation compared to cutaneous melanoma. Pigment Cell Melanoma Research, v. 38, n. 3, p. e70027, maio 2025. DOI: 10.1111/pcmr.70027. PMID: 40405404; PMCID: PMC12099029. Acesso em: maio 2025.
WORLD HEALTH ORGANIZATION; INTERNATIONAL LABOUR ORGANIZATION; PRÜSS-ÜSTÜN, A.; WOLF, J.; DRISCOLL, T.; STEENLAND, K.; et al. The effect of occupational exposure to solar ultraviolet radiation on malignant skin melanoma and non-melanoma skin cancer: a systematic review and meta-analysis from the WHO/ILO Joint Estimates of the Work-related Burden of Disease and Injury. Geneva: WHO, 2021. Disponível em: https://doi.org/10.1016/j.envint.2023.108226. Acesso em: maio 2025.
